• Ocular Therapeutix submits supplemental NDA for Dextenza

    6 days ago - By Healio

    A supplemental new drug application for Dextenza has been submitted to the FDA to expand its indication to include the treatment of ocular inflammation after ophthalmic surgery, Ocular Therapeutix announced in a press release.
    Dextenza was approved by the FDA in November 2018 and is currently indicated for postsurgical ocular pain.
    “Submission of this sNDA on the heels of the initial Dextenza approval is another significant milestone for Ocular Therapeutix. The potential market opportunity for postoperative ocular pain and inflammation is substantial, and
    Read more ...